| Literature DB >> 9135032 |
T D Penning1, J J Talley, S R Bertenshaw, J S Carter, P W Collins, S Docter, M J Graneto, L F Lee, J W Malecha, J M Miyashiro, R S Rogers, D J Rogier, S S Yu, E G Burton, J N Cogburn, S A Gregory, C M Koboldt, W E Perkins, K Seibert, A W Veenhuizen, Y Y Zhang, P C Isakson.
Abstract
A series of sulfonamide-containing 1,5-diarylpyrazole derivatives were prepared and evaluated for their ability to block cyclooxygenase-2 (COX-2) in vitro and in vivo. Extensive structure-activity relationship (SAR) work was carried out within this series, and a number of potent and selective inhibitors of COX-2 were identified. Since an early structural lead (1f, SC-236) exhibited an unacceptably long plasma half-life, a number of pyrazole analogs containing potential metabolic sites were evaluated further in vivo in an effort to identify compounds with acceptable pharmacokinetic profiles. This work led to the identification of 1i (4-[5-(4-methylphenyl)-3-(trifluoromethyl)- H-pyrazol-1-yl]benzenesulfonamide, SC-58635, celecoxib), which is currently in phase III clinical trials for the treatment of rheumatoid arthritis and osteoarthritis.Entities:
Mesh：
Substances：
Year: 1997 PMID： 9135032 DOI： 10.1021/jm960803q
Source DB: PubMed Journal: J Med Chem ISSN： 0022-2623 Impact factor: 7.446